Abstract: ［Abstract］ Objective To evaluate the efficacy and adverse reaction of the chemotherapy by apatinib or apatinib combined with traditional Chinese medicine in treating with advanced NSCLC. Methods This was a prospective study from Jan 2017 to Sep 2018， and 59 patients with a confirmed diagnosis of stageⅢb?ⅣNSCLC. Among them，31 patients receive treatment of Apatinib alone （control group）， 28 patients receive combined treatment of TCM and Apatinib （treatment group）. Results 1. Comparison of recent objective efficacy： The ORR （14.29%） and DCR （60.71%） of the treatment group were lower than the ORR （19.35%） and DCR （64.52%） of the control group， but there were no significant difference between the two group （P>0.05）. Comparison of the survival time： The mPFS was 3.33 months in treatment group and 3.0 in control group， and there was no significant difference between the groups （P>0.05）. The MST in the treatment group was 5.17 months， and the control group was 4.9 months （P>0.05 when compared between two group）. 2. Comparison of the side effect rate and safety： The rate of hypertension， proteinuria and bone marrow suppression in the treatment group was lower than that of the control group， and the difference of proteinuria between the groups was statistically significant （P<0.05）. Conclusion Compared with apatinib， Apatinib combine with TCM has the same efficacy in treatment of advanced non?small?cell lung cancer. Apatinib combine with TCM can antagonize the toxic and side effects caused by apatinib， improve the tolerance of patients and improve the quality of life of patients.

Key words: apatinib, wild type, traditional Chinese medicine, advanced NSCLC

摘要： ［摘要］ 目的 本研究旨在进一步探讨甲磺酸阿帕替尼口服联合中医辨证论治治疗晚期EGFR野生型肺腺癌患者的有效性和安全性。方法 收集2017年1月至2018年9月诊治的IIIB-IV期EGFR野生型、肺腺癌患者，对照组（接受阿帕替尼单药治疗）患者31例，治疗组（接受阿帕替尼+中医辨证中药治疗）28例。对2组患者进行疗效、不良反应观察。结果 近期客观疗效对比，治疗组ORR（14.29%）、DCR（60.71%）稍低于对照组的ORR（19.35%）及DCR（64.52%），差异无统计学意义（P>0.05）；生存情况对比，治疗组mPFS为3.33个月，对照组mPFS为3.0个月，组间比较无明显统计学意义（P>0.05）；治疗组MST为5.17个月，对照组MST为4.9个月，组间差异无明显统计学意义（P>0.05）；不良反应发生率对比，治疗组在高血压、蛋白尿、骨髓抑制方面发生率明显低于对照组，而蛋白尿组间差异具有统计学意义（P<0.05）。结论 治疗组与对照组在近期疗效及总生存方面无统计学差异；中医辨证中药治疗在一定程度上拮抗阿帕替尼导致的毒副作用，提高患者治疗耐受性，改善患者生活质量，对晚期NSCLC患者的治疗有积极影响。

关键词: 野生型, 阿帕替尼, 非小细胞肺癌, 中医辨证